RGEN Repligen Corporation

Repligen Corporation to Present at Upcoming Investor Conferences

Repligen Corporation to Present at Upcoming Investor Conferences

WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences.

  • William Blair 41st Annual Growth Stock conference being held June 1 - 3.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, June 1, at 1:40 p.m. EST.  
  • Jefferies Virtual Healthcare Conference being held June 1 - 3.   Tony J. Hunt, President and Chief Executive Officer and Jon K. Snodgres, Chief Financial Officer, will participate in a fireside chat on Thursday, June 3, at 2:30 p.m. EST.

A live webcast of the discussions will be accessible through the  section of the Company’s website, and will be available for replay for a limited period of time following the conference event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881



EN
25/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Repligen Corporation

 PRESS RELEASE

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results a...

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE...

 PRESS RELEASE

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2025 financial results on Tuesday, February 24, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2025....

 PRESS RELEASE

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Ele...

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated1, Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective this March 13th. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027. “On behalf of Re...

 PRESS RELEASE

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Confere...

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 13 at 2:15 p.m. PT. A live webcast of the conference presentations will be accessible through Repligen’s  websit...

 PRESS RELEASE

Repligen Introduces Next-Generation Chromatography Resins to Advance N...

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new high-performance chromatography resins: AVIPure® HiPer™ AAV9 and AVIPure® HiPer™ AAV8 affinity resins, along with HiPer™ QA anion exchange resin, expanding the company’s growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™ DuloCore...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch